Navigation Links
International Steering Committee for RVX-208 IVUS Trial Formed

Dr. Steven Nissen to Chair Steering Committee for Landmark ApoA-I Trial

TSX Exchange Symbol: RVX

CALGARY, Oct. 7 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce the formation of the Steering Committee for the RVX-208 Phase 2b clinical trial assessing atherosclerosis by IVUS (Intravascular Ultrasound). This is a study in Acute Coronary Syndrome patients expected to start in 2009.

"We are honored to have an experienced and highly esteemed group of internationally recognized cardiologists to lead this important IVUS atherosclerosis study," said Mr. Donald J. McCaffrey, President and CEO of Resverlogix. "ApoA-IMilano infusions have previously been shown to be the most efficient means to reduce atherosclerosis, we will now test the hypothesis that a permanent endogenous ApoA-I increase by oral administration of RVX-208 has the same capacity".

Appointed members of the Phase 2b IVUS Steering Committee include:

Chairman: Dr. Steven Nissen, M.D., Chairman of the Department of

Cardiovascular Medicine located on the main campus of Cleveland


Principal Investigator: Dr. Stephen Nicholls, M.B.B.S, Ph.D., Medical

Director of Intravascular Ultrasound and Angiography Core

Laboratories at Cleveland Clinic and Clinical Director of the

Cleveland Clinic Center for Cardiovascular Diagnostics and


Dr. Christie M. Ballantyne, M.D., Associate Chief and Professor,

Section of Atherosclerosis and Lipoprotein Research, Baylor College

of Medicine, Houston, Texas.

Dr. John J.P. Kastelein, M.D., Ph.D., Professor of Medicine and

Chairman of the Department of Vascular Medicine at the Academic

Medical Centre (AMC) of the University of Amsterdam, where he holds

the Strategic Chair of Genetics of Cardiovascular Disease and is the

Director of the Atherosclerosis Research Group.

Dr. Allen Taylor, M.D., Chief, Cardiology Service, Professor of

Medicine, USUHS Walter Reed Army Medical Center in Washington, D.C.

The role of the Steering Committee is to provide overall supervision of the trial and ensure that it is being conducted in accordance with the principles of Good Clinical Practice and FDA regulations. The Steering Committee will agree on the trial protocol, any protocol amendments and provide advice to the investigators on all aspects of the trial.

Apolipoprotein A-I (ApoA-I), the main component of high-density lipoprotein (HDL) represent the body's natural defense system against atherosclerosis by mediating reverse cholesterol transport, i.e. transport of peripheral cholesterol including that of the vessel wall to the liver for elimination from the body. In multiple human and animal studies over-expression or repeated infusion of ApoA-I inhibit progression and induce regression of atherosclerosis in animals and humans.

RVX-208, a novel small molecule drug that facilitates endogenous ApoA-I production, is positioned as an emerging drug that holds the most promise for the treatment of atherosclerosis. RVX-208 is designed to increase ApoA-I production and thereby raise HDL levels thus enhancing HDL functionality to augment reverse cholesterol transport.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet needs. The NexVas(TM) program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as acute coronary syndrome, diabetes, Alzheimer's disease and other vascular disorders. The Company's secondary focus is TGF-Beta Shield(TM), a program that aims to address burgeoning grievous diseases, such as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

SOURCE Resverlogix Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
2. The Government of Quebec and the New Canadian Government Invest in the Creation of an International Biobank
3. International Isotopes Inc. Announces Completion of an Exclusive Distributor Agreement for Sales of New Style Transportation Containers
4. Arrow International Files and Mails Definitive Proxy Materials
5. Niceware International Announces Licensed Vendor Status with ICCBBA, Inc. to Provide ISBT 128-compliant Software
6. DuPont, Genencor International and Tate & Lyle Honored for Groundbreaking Work in Developing Bio-PDO(TM)
7. Viragen International to Reverse Split Its Common Stock
8. Tutogen Medical, Inc. and Zimmer Holdings, Inc. Announce Agreement for International Distribution of Biological Products
9. Zimmer and Tutogen Announce Agreement for International Distribution of Biological Products
10. PAREXEL International to Present at Thomas Weisel Partners Healthcare Conference
11. Biosafety and Biosecurity International Conference 2007 to be held in Abu Dhabi from November 12 to 14
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... ... in scientifically backed, age-defying products, is featured as the cover story and ... success and unrivaled opportunities that Nerium provides. Success from Home magazine routinely ...
(Date:12/1/2015)... 1, 2015 Dr. Harry Lander , President of Regen, ... Chief Science Officer and recruits five distinguished ... , President of Regen, expands his role to include ... recruits five distinguished scientists to join advisory team ... his role to include serving as Chief ...
(Date:12/1/2015)... DUBLIN , December 1, 2015 /PRNewswire/ ... the addition of the  "2016 U.K. Virology ... Segment Forecasts for 100 Tests, Supplier Shares ... Opportunities"  report to their offering.  --> ... of the  "2016 U.K. Virology and Bacteriology ...
(Date:11/30/2015)... ... November 30, 2015 , ... Global Stem Cells Group ... in the Santiago Marriott. The Global Stem Cells Group GMP facility is equipped ... of qualified medical researchers and practitioners, experienced in administering stem cell protocols using ...
Breaking Biology Technology:
(Date:11/12/2015)... 2015  Arxspan has entered into an agreement ... for use of its ArxLab cloud-based suite of ... partnership will support the institute,s efforts to electronically ... information internally and with external collaborators. The ArxLab ... the Institute,s electronic laboratory notebook, compound and assay ...
(Date:11/10/2015)...  In this report, the biomarkers market ... type, application, disease indication, and geography. The ... consumables, services, software. The type segments included ... biomarkers, and validation biomarkers. The applications segments ... drug discovery and development, personalized medicine, disease ...
(Date:11/9/2015)... SAN JOSE, Calif. , Nov. 9, 2015 /PRNewswire/ ... of human interface solutions, today announced broader entry into ... of vehicle-specific solutions that match the pace of consumer ... drivers, and biometric sensors are ideal for the automotive ... the vehicle. Europe , ...
Breaking Biology News(10 mins):